| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Affectis Pharmaceuticals AG - Product Pipeline Review - 2012
Market |
Healthcare and Medical |
Report Type |
Company Profile |
Country |
Global |
Published |
28 June 2012 |
Number of Pages |
40 |
1-3 hours, 24 hour max |
|
Publisher |
Global Markets Direct |
File Format |
This report is built using data and information sourced from our proprietary databases, Affectis Pharmaceuticals AGs corporate website, SEC filings, investor presentations and featured press releases, both from Affectis Pharmaceuticals AG and industry-specific third party sources, put together by our team.
Scope
- Affectis Pharmaceuticals AG - Brief Affectis Pharmaceuticals AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Affectis Pharmaceuticals AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Affectis Pharmaceuticals AG with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Affectis Pharmaceuticals AGs pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Affectis Pharmaceuticals AGs strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Affectis Pharmaceuticals AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Affectis Pharmaceuticals AGs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Affectis Pharmaceuticals AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Affectis Pharmaceuticals AG and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Affectis Pharmaceuticals AG; Affectis Pharmaceuticals AG - Key Therapeutics; Affectis Pharmaceuticals AG - Pipeline Overview and Promising Molecules; Affectis Pharmaceuticals AG - News; Affectis Pharmaceuticals AG - Latest Updates; Affectis Pharmaceuticals AG - Pipeline; Affectis Pharmaceuticals AG - Discontinued/Dormant Projects
Visitor Comments
|
All posts are pre-moderated and must obey the house rules. |
|
Competitor Tracking
Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
US herbal products market grew by 3% through 2012
US analgesics market led by Pfizer's Advil
US emergency contraception market grew by 8% through 2012
US consumer health market to benefit from supplements continuing to perform well
US digestive remedies market to benefit from an unexpected surge in cases of norovirus
